News

Concord Biotech Q2 profit slides 34%; board clears new venturesConcord Biotech also reported drops in revenue, EBITDA and margins for Q2FY26. Shares of Concord Biotech Ltd ended marginally higher on Thursday, November 13, up 0.04% at ₹1,463.80 on the NSE.By Megha Rani   November 13, 2025, 8:34:15 PM IST (Published)1 Min ReadConcord Biotech Ltd on Thursday, November 13, reported a 33.6% year-on-year decline in its net profit at ₹63.6 crore for Q2FY26, compared to ₹95.7 crore in the same period last year.

The company's revenue also declined 20.4% to ₹247.1 crore from ₹310.2 crore.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) fell 35.3% to ₹88.4 crore. The operating margin slipped to 35.8% from 44% a year ago.

The company’s board has approved a proposal to acquire 100% equity in Celliimune Biotech Pvt Ltd, marking a strategic expansion move in the biotech segment, stated the company's exchange filing.

Additionally, the board cleared an investment of up to ₹10 crore in a captive hybrid solar power project for its Limbasi plant, reinforcing the company’s commitment to sustainable operations.

Shares of Concord Biotech Ltd ended marginally higher on Thursday, November 13, by 0.04% at ₹1,463.80 on the NSE.

Also Read: TVS Supply Chain Q2 Results | Net profit spikes 54% on cost efficiency, strong executionContinue Reading(Edited by : Shoma Bhattacharjee)Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsAcquisitionsinvestmentNet profitQ2 EarningsQ2 resultsrevenue